We have examined a wide range of cultured human tumor cell lines and found that a specific subset of tumors expresses the cholecystokinin (CCK) gene. All neuroepitheliomas (eight) and Ewing sarcoma (eight) cell lines that were tested express CCK RNA. In addition, two of six rhabdomyosarcoma cell lines also express the CCK gene, suggesting that rhabdomyosarcomas are probably heterogenous and that a subset may be similar to Ewing sarcoma and neuroepithelioma. Very few of the positive tumors express completely processed immunoreactive CCK. However, we have used a radioimmunoassay that detects the CCK precursor to demonstrate synthesis of CCK precursor-like peptides by all of the Ewing sarcoma and neuroepithelioma lines that were tested and by the rhabdomyosarcoma cell line that expresses CCK mRNA. These data demonstrate a consistent association of CCK gene expression with a specific group of human neoplasms. The data also add credence to the theory that Ewing sarcoma and neuroepithelioma are derived from the same transformed cell type. Finally, our results suggest that CCK gene expression may serve as a marker to distinguish these tumors, which are considered to be small-round-cell tumors of childhood, from other pediatric tumors.
Cholecystokinin (CCK) is a peptide hormone that was first isolated from small intestine and that stimulates gall bladder contraction and pancreatic secretion (1) . High levels of CCK have also been found in central nervous system neurons, where the peptide is thought to function as a neurotransmitter (2) (3) (4) (5) (6) (7) . A syndrome due to ectopic production of CCK by specific tumors has not been described, although immunoreactive CCK peptides have been detected in aqueous extracts derived from a group of pituitary tumors and from 16 medullary thyroid tumors obtained at surgery (8, 9) . These observations suggest that CCK may be synthesized by specific groups of human neoplasms.
CCK mRNA and peptides are expressed in two tumor cell lines derived from human neuroepitheliomas (10) . Neuroepitheliomas are nerve cell tumors that occur throughout the body and are most commonly detected in the first and second decades of life (11) . These tumors have been noted to resemble Ewing sarcoma, a pediatric bone tumor, in that both tumor types are histologically similar, share the same karyotypic abnormality [t(11;22)(q23;ql2)] (12), manifest a common pattern of protooncogene expression, and are cholinergic (13) . In this study, we measured the levels of CCK mRNA, CCK biosynthetic precursor peptides, and fully processed CCK in a larger group of human tumor ccll lines. We found that eight of eight neuroepitheliomas and eight of eight Ewing sarcoma cell lines expressed CCK mRNA. Two cell lines derived from human rhabdomyosarcomas were also found to synthesize this hormone. None of a variety of other cultured human tumor lines, including nine neuroblastomas, expressed the CCK gene. All of the tumor cell lines that expressed CCK mRNA were also found to secrete prohormonal forms of CCK, but only one was able to process the precursor material sufficiently to generate immunoreactive CCK octapeptide (CCK-8)-like peptides. These data provide a consistent demonstration of CCK gene expression by a specific subset of human tumors. Radioimmunoassay of CCK and CCK-Precursor-Related Peptide (CCK-PRP). Tissue culture media and boiling-water extracts ofcentrifuged cellular pellets were assayed in a CCK carboxyl-terminal radioimmunoassay system (34) . The amidated carboxyl-terminal phenylalanine ofCCK is required for recognition by this antibody. CCK-8, CCK-33, and gastrin (G-17) crossreact equally with this antibody on a molar basis (Fig. 1) . The same extracts were also assayed in a radioimmunoassay system specific for the carboxyl-terminal 9-amino acid extension of prepro-CCK, CCK-PRP (35) . The antibody used in this assay recognizes CCK prohormonal material, as well as the carboxyl-terminal 9-amino acid extension peptide shown to exist free in mammalian brain and gut (35) (36) (37) (38) . Specificities of these antibodies are summarized in Fig. 1 . Gel filtration ofimmunoreactive material present in culture media and cellular extracts was performed with Sephadex G-50 and G-25 superfine (34, 35) . The immunoreactivity present in cells and media was also subjected to digestion with L-1-tosylamido-2-phenylethyl chloromethyl ketone (TPCK)-treated trypsin (10 ug/ml) in phosphate buffer (pH 7.5) at 37°C. The reaction was terminated by boiling the mixture for 5 min. The reaction products were then subjected to Sephadex gel filtration and the column eluates were analyzed with the CCK-PRP radioimmunoassay system. RNase Protection Assays. RNA was extracted from 108 tumor cells with guanidinium thiocyanate and sedimented through a cesium chloride cushion (39 FIG. 1 . Specificity ofanti-CCK antisera. Biologically active CCK is generated by cleavage of the CCK precursor at the Gly-Arg-Arg sequence that joins the carboxyl terminus of CCK to a 9-amino acid flanking peptide at the extreme carboxyl terminus of the precursor. This cleavage is followed by amidation of the carboxyl-terminal phenylalanine of CCK-8 generated by the cleavage.
MATERIALS AND METHODS

RESULTS
Initially we surveyed a selection of cell lines from the American Type Culture Collection for expression ofthe CCK gene. These included one neuroepithelioma (SK-N-MC, which was described previously) (10, 17) 18, p. 197) , and one medulloblastoma (TE671) (ref. 18, pp. 203-204) . All the tumor cell lines were grown according to published procedures. At confluence, RNA was extracted from the cell monolayer and the levels of CCK RNA were measured in an RNase protection assay specific for mouse and human CCK ( Fig. 2) (10, 40) . The labeled RNA probe was derived from the third exon of the mouse CCK gene. The extensive homology between mouse and human in this region allows the detection of a specific protected 110-bp fragment when hybridized to mRNA from mouse and several bands of this approximate size when hybridized to human mRNA (10) . The presence of multiple bands when human RNA is hybridized to the mouse antisense RNA probe is most likely due to minor dishomologies between the two species in this region. The undigested 32P-labeled probe runs as a single band of 160 bp (10) . The presence of protected RNAs in this size range is diagnostic of CCK transcripts. CCK RNA was detected in the two Ewing sarcoma cell lines (SK-ES and RD-ES; Fig. 2 ). CCK RNA was also detected in the neuroepithelioma SK-N-Mc (data not shown), as previously reported (10) . No CCK RNA was detected in the other cell lines with the exception of A673, a cell line that was originally thought to be derived from a rhabdomyosarcoma but that has never been shown to express muscle-specific markers (M.A.I., unpublished data). We believe this tumor to have been derived from an embryonal rhabdomyosarcoma. The RNA from the cell lines not expressing CCK RNA was intact as determined by equivalent levels of actin RNA detected in each ofthe samples by an RNase protection assay specific for this gene (ref. 42 ; data not shown).
To determine whether the tumor cells that synthesize CCK RNA produce and process CCK peptides, conditioned media were assayed in both the CCK and CCK-PRP radioimmunoassay systems ( Fig. 1; refs. 34 and 35 ). CCK-PRP is the extreme carboxyl-terminus nonapeptide of prepro-CCK, and the specific antibody used in these studies detects the CCK prohormone and the cleaved nonapeptide on an equimolar basis. The CCK-8 radioimmunoassay (34) (Fig. 3) . In addition, these cell lines all synthesized immunoreactive CCK-PRP ( Fig. 1 The classification ofTE671 [which tested negative for CCK (Table 1) ] as a medulloblastoma (which is included in the small-round-cell class) has proven incorrect (30) . It has been suggested that TE671 is, in fact, a rhabdomyosarcoma that expresses muscle markers (27) .
Although CCK mRNA and CCK peptides are strongly expressed by the Ewing and neuroepithelioma cell lines, we have not yet determined whether these processes occur in these neoplasms in vivo. The majority of CCK-expressing tumors that we have characterized did not fully process the preprohormone so as to generate immunoreactive CCK, based on reactivity with the two antisera that were utilized (34, 35) . Thus even if the CCK gene is activated in these tumors in vivo, a clinical syndrome due to overproduction of the classically recognized form of the hormone should be associated with these tumors only rarely. It is unclear whether the CCK prohormone or CCK-PRP have any biologic activity; however, ifCCK mRNA and CCK peptides are shown to be consistently expressed by Ewing sarcomas and neuroepitheliomas in vivo, the assays described above might be useful in differentiating these tumors from other tumors of childhood that do not express the CCK gene (e.g., neuroblastomas, osteogenic sarcomas). Distinguishing among these small-round-cell tumors is quite important, since each type appears to respond to a different treatment regimen (46) .
In conclusion, we report the consistent demonstration of CCK gene expression and CCK peptide synthesis by specific types of human tumors. Our finding that this neuropeptide is expressed by all Ewing sarcomas and neuroepitheliomas studied provides further evidence for their common neural origin and extends the emerging body of data indicating that these tumors arise in the same cell type. 
